Tissue-specific expression of these splice variantsregulates interactions in embryonic development,tissue maintenance and repair, and cancer.Alterations in FGFR2 splicing are involved inepithelial mesenchymal transition that producesinvasive, metastatic features during tumorprogression.Recent research has elucidated regulatory factors that determinethe splice choice both on the level of exogenous signaling eventsand on the RNA-protein interaction level. The gene discussed is FGFR2; the disease is cancer.